{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:00:27Z","timestamp":1771974027506,"version":"3.50.1"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,11]]},"DOI":"10.7759\/cureus.45012","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T09:00:26Z","timestamp":1694422826000},"source":"Crossref","is-referenced-by-count":4,"title":["Respiratory Syncytial Virus Prevention: A New Era of Vaccines"],"prefix":"10.7759","author":[{"given":"Calvin Yee Fen","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salman J","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fnu","family":"Vishal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadaf","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syeda Fatima","family":"Murtaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis AO","year":"2021","unstructured":"Aliprantis AO, Shaw CA, Griffin P, et al.. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum Vaccin Immunother. 2021, 17:1248-61. 10.1080\/21645515.2020.1829899","journal-title":"Hum Vaccin Immunother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01675","article-title":"Biology of infection and disease pathogenesis to guide RSV vaccine development","volume":"10","author":"Boyoglu-Barnum S","year":"2019","unstructured":"Boyoglu-Barnum S, Chirkova T, Anderson LJ. Biology of infection and disease pathogenesis to guide RSV vaccine development. Front Immunol. 2019, 10:1675. 10.3389\/fimmu.2019.01675","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt LL","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, et al.. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med. 2022, 386:837-46. 10.1056\/NEJMoa2110275","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(22)00321-2","article-title":"Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials","volume":"7","author":"Sim\u00f5es EA","year":"2023","unstructured":"Sim\u00f5es EA, Madhi SA, Muller WJ, et al.. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023, 7:180-9. 10.1016\/S2352-4642(22)00321-2","journal-title":"Lancet Child Adolesc Health"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion F protein vaccine in older adults","volume":"388","author":"Papi A","year":"2023","unstructured":"Papi A, Ison MG, Langley JM, et al.. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023, 388:595-608. 10.1056\/NEJMoa2209604","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/187360-respiratory-syncytial-virus-prevention-a-new-era-of-vaccines","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:05:14Z","timestamp":1707509114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/187360-respiratory-syncytial-virus-prevention-a-new-era-of-vaccines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":5,"URL":"https:\/\/doi.org\/10.7759\/cureus.45012","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,11]]}}}